Comparetive Observation Of Nimodipine And Edaravone In The Treatment Of Ischemic Brain Injury After Intracerebral Hemorrhage

BackgroundCerebral hemorrhage after ischemic brain injury secondary to secondary disease in primary disease,if not given timely and effective treatment and intervention,not only will cause the original disease aggravated,but also increase the primary disease treatment Difficulty,greatly enhance the incidence of a variety of complications,increased morbidity,mortality,the patient's physical rehabilitation and life and health is extremely unfavorable.Clinically,the treatment of ischemic brain injury and cerebral hemorrhage itself,the treatment of disease is fundamentally different.Especially in the intervention and treatment of disease,the two diseases in the choice of antiplatelet or anticoagulant drugs and hemostatic drugs and other aspects of each other.Combined with a long time,clinical cerebral hemorrhage after ischemic brain injury cognition and intervention research is relatively small,resulting in until now,the clinical treatment is still lack of a complete,systematic,based on multi-center and large-scale Treatment programs.ObjectiveIntracerebral hemorrhage(ICH)is a common neurological disease in clinical practice.Ischemic brain injury is one of the most common types of complications after ICH.The aim of this study was to analyze the safety and efficacy of nimodipine in the treatment of ischemic brain injury after intracerebral hemorrhage.The aim of this study was to evaluate the therapeutic advantages and value of nimodipine.MethodsSeventy-four patients with ischemic brain injury after cerebral hemorrhage were enrolled in this study.The patients were included in the study from September 2014 toAugust 2015.All of the patients in this study had clinical symptoms,imaging findings and laboratory results obtained in line with the parameters of ischemic brain injury after cerebral hemorrhage diagnostic criteria.The 74 patients included in the study were divided into the observation group included 38 patients and the control group included36 patients.Two groups of patients in our hospital after diagnosis,the two groups of patients received the same conventional treatment regimens,conventional treatment,including correction of water and electrolyte disorders,anti-infection,reduce intracranial pressure.On the basis of the above conventional treatment,the patients in the control group were treated with intravenous injection of edaravone,and the patients in the observation group were treated with oral nimodipine.2 weeks for a medication cycle,the total treatment time for 3 courses.After the end of the treatment period,the two groups of patients with general information,clinical treatment efficiency,the incidence of adverse reactions,neurological deficit score and daily living ability of clinical comparative analysis.To evaluate the clinical value of nimodipine in the treatment of ischemic brain injury after intracerebral hemorrhage by comparative analysis.Results(1)There was no significant difference in sex,age,co-morbidity and disease severity between the two groups(P> 0.05).(2)After treatment,the effective rate of clinical treatment was 92.11% in the observation group and 72.22% in the control group.The difference between the two groups was statistically significant Statistical significance(?2=5.581,P=0.023).(3)Before treatment,there was no significant difference between the two groups(t=0.558,P=0.572;t=0.022,P=0.982).After the treatment,the neurological deficit score and the daily living ability score of the observation group and the control group were not significantly different The scores of neurological deficits and daily living ability of the patients were significantly better than those of the control group,and the difference was statistically significant(t=9.649,P=0.013;t=4.923,P=0.029)..(4)After treatment,the adverse reaction rate was 5.26% in the 38 patients in the observation group and 19.44% in the 36 patients in the control group.The incidence of adverse reactions in the observation group was significantly higher than that in the control group The difference between the two groups was statistically significant(?2=4.654,P=0.034).ConclusionNimodipine can improve the clinical symptoms,reduce the degree of ischemic brain injury and improve the quality of life of patients with ischemic brain injury after cerebral hemorrhage.At the same time,the neurological function and brain injury of patients with ischemic brain injury after cerebral hemorrhage were significantly improved after Nimodipine treatment,and the degree of dependence on family members in daily life was reduced and the ability of self-care was improved significantly.In short,nimodipine treatment of cerebral hemorrhage after cerebral ischemic brain injury is relatively high,patients with side effects after medication,drug safety can be guaranteed.